{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:04:43Z","timestamp":1789707883292,"version":"4.0.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Steroid-refractory acute severe ulcerative colitis is a medical emergency associated with a substantial risk of colectomy. Although infliximab and calcineurin inhibitors are established rescue treatments, comparative evidence regarding alternative drugs, infliximab dosing strategies, and newer small-molecule therapies remains limited. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of available medical rescue strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Embase, Scopus, Web of Science, and Cochrane CENTRAL were searched from inception through June 30, 2026. Randomized controlled trials and comparative observational studies enrolling adults hospitalized with steroid-refractory acute severe ulcerative colitis were eligible. Separate frequentist random-effects network meta-analyses were conducted for colectomy at approximately 12\u201314 weeks, colectomy during hospitalization or within 30 days, colectomy at approximately 12 months, and serious adverse events. Effects were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Risk of bias was assessed using RoB 2 and ROBINS-I.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 5, 498 records identified, 18 studies involving 1, 529 participants met the eligibility criteria, including three randomized trials and 15 observational studies. At approximately 12\u201314 weeks, ciclosporin was associated with higher odds of colectomy than standard-dose infliximab (OR 2.19, 95% CI 1.17\u20134.12). Neither high-dose infliximab (OR 2.92, 95% CI 0.42\u201320.26) nor accelerated infliximab (OR 4.57, 95% CI 0.88\u201323.75) differed significantly from standard-dose infliximab. Ciclosporin was also associated with higher odds of early colectomy (OR 3.05, 95% CI 1.38\u20136.77) and 12-month colectomy (OR 3.65, 95% CI 1.98\u20136.72) than standard-dose infliximab. Tacrolimus and accelerated infliximab did not differ significantly from standard-dose infliximab at either time point. Serious adverse events were similar between ciclosporin and infliximab (OR 0.94, 95% CI 0.54\u20131.63). The networks contained no closed loops, and most observational studies were judged to have a serious risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the combined randomized and observational evidence, standard-dose infliximab was associated with lower colectomy odds than ciclosporin, without a detectable difference in serious adverse events. No consistent advantage was demonstrated for accelerated or high-dose infliximab. Because the apparent efficacy advantage of infliximab was driven predominantly by observational studies, whereas randomized trials showed comparable outcomes, the findings should be interpreted cautiously. Further adequately powered randomized comparisons incorporating contemporary biologic-exposed populations and newer small-molecule therapies are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261412884.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1937925","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:36:46Z","timestamp":1789706206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative outcomes of advanced medical rescue therapies in steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"5","author":[{"given":"Mohamad Yousef","family":"Alabdallat","sequence":"first","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Al Ta\u2019ani","sequence":"additional","affiliation":[{"name":"Allegheny General Hospital, Allegheny Health Network","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Bakain","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Dwairy","sequence":"additional","affiliation":[{"name":"Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghannam","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Atasi","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Mashal","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences","place":["Little Rock, AR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Moghib","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kasr Al-Ainy, Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Bakheet","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed G.","family":"Jagroo","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Hehr","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Salem","sequence":"additional","affiliation":[{"name":"Maimonides Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Cheung","sequence":"additional","affiliation":[{"name":"Brookdale University Hospital and Medical Center","place":["Brooklyn, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000199983","article-title":"Cortisone in ulcerative colitis: final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.12442","article-title":"Review article: updated management of acute severe ulcerative colitis\u2014from steroids to novel medical strategies","volume":"11","author":"Calm\u00e9jane","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline Update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa226","article-title":"Ciclosporin or infliximab as rescue therapy in acute glucocorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.07.025","article-title":"Comparative effectiveness of tofacitinib vs upadacitinib for the treatment of acute severe ulcerative colitis","volume":"24","author":"Honap","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis","volume":"18","author":"Huang","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5, updated August 2024 [Internet\n          \n          \n            \n              Higgins\n              JPT\n            \n            \n              Thomas\n              J\n            \n            \n              Chandler\n              J\n            \n            \n              Cumpston\n              M\n            \n            \n              Li\n              T\n            \n            \n              Page\n              MJ\n            \n          \n          Cochrane\n          \n          2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-0716-1566-9_3","article-title":"Fixed- and random-effects models","volume":"2345","author":"Kanters","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range, and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.903","article-title":"Standard deviations and standard errors","volume":"331","author":"Altman","year":"2005","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.99.3.400","article-title":"Meta-analytic procedures for combining studies with multiple effect sizes","volume":"99","author":"Rosenthal","year":"1986","journal-title":"Psychol Bull"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B26","article-title":"Undertaking network meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5","author":"Chaimani","year":"2024"},{"key":"B27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5358-z","article-title":"High-dose infliximab rescue therapy for hospitalized acute severe ulcerative colitis does not improve colectomy-free survival","volume":"64","author":"Chao","year":"2019","journal-title":"Dig Dis Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14072","article-title":"Predicting response after infliximab salvage in acute severe ulcerative colitis","volume":"33","author":"Choy","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/apt.12375","article-title":"Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs infliximab","volume":"38","author":"Croft","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06958.x","article-title":"Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis","volume":"27","author":"Dean","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5009\/gnl14120","article-title":"Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: a Korean, retrospective, single-center study","volume":"9","author":"Kim","year":"2015","journal-title":"Gut Liver"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae051","article-title":"Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China","volume":"12","author":"Liu","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.11.021","article-title":"Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study","volume":"6","author":"Mocciaro","year":"2012","journal-title":"J Crohns Colitis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12876-026-04847-w","article-title":"Early infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis","volume":"26","author":"Mohamedrashed","year":"2026","journal-title":"BMC Gastroenterol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000101","article-title":"Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks","volume":"20","author":"Naves","year":"2014","journal-title":"Inflammation Bowel Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15508","article-title":"Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis","volume":"36","author":"Song","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.70055","article-title":"Comparison of tacrolimus and infliximab for acute severe ulcerative colitis in hospitalized adults: a retrospective study","volume":"27","author":"Sror","year":"2026","journal-title":"J Dig Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","article-title":"Hypoalbuminemia and bandemia predict failure of infliximab rescue therapy in acute severe ulcerative colitis","volume":"66","author":"Syal","year":"2021","journal-title":"Dig Dis Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1937925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:37:01Z","timestamp":1789706221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1937925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":42,"alternative-id":["10.3389\/fgstr.2026.1937925"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1937925","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1937925"}}